WHY AND WHEN TO REQUEST FOR A PET/CT SCAN IN A LUNG CANCER PATIENT?
DOI:
https://doi.org/10.48729/pjctvs.26Abstract
This review will focus on whole-body functional imaging applied to lung cancer disease and patient management. Lung cancer needs to be avoided… (but if not well succeeded), suspected, screened, histologically confirmed, anatomically inventoried, prognostically staged, molecularly characterized, genetically studied and finally, therapeutically managed. Functional imaging using 18F-fluoro-deoxy-glucose (FDG) is a non-invasive method that is widely used in oncologic disease, mainly for clinical staging and re-staging, with impact on therapy planning. For lung cancer, the functional imaging with FDG-PET/CT is used for clinical staging and also to provide information on a pre-diagnostic phase, to categorize lung nodules according to the metabolic risk of malignancy. Clinicians need to be aware of the different possibilities of the functional imaging information, to provide the better use of it. This review will focus on data from the different medical fields that are considered important to informed decision making when asking for functional imaging in the daily clinical routine of a lung cancer patient.
Downloads
References
American Joint committee on cancer, AJCC cancer staging manual, 8th Edition.2017
Eugene Lin, Abass Alavi. PET and PET/CT: A Clinical Guide. Thieme Medical Publishers, Inc 2005
Keyes JW Jr. SUV: standard uptake or silly useless value? J Nucl Med. 1995;36:1836–1839
Eric P. Visser, Otto C. Boerman and Wim J.G. Oyen. SUV: From Silly Useless Value to Smart Uptake Value: J Nucl Med
February 2010 vol. 51 no. 2 173-175
K Macdonald , J Searle, I Lyburn. The role of dual time point FDG PET imaging in the evaluation of solitary pulmonary
nodules with an initial standard uptake value less than 2.5: ClinRadiol. 2011 Mar;66(3):244-50.
Travis WD, Brambilla E et al. WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart; WHO Classification of Tumours, 4th Edition, Volume 7
Daniel Morgensztern, Shean Huey Ng, Feng et al. Reference Trends in Stage Distribution for Patients with Non-small Cell Lung Cancer: A National Cancer Database Survey. Journal of Thoracic Oncology • Volume 5, Number 1, January 2010
Bum Soo Kim , In Joo Kim, et al. Predictive value of F-18 FDG PET/CT for malignant pleural effusion in non-small cell lung cancer patient: Onkologie. 2011;34(6):298-303. Epub 2011 May 20.
Junkai Li, Wen Xu, et al. Meta-analysis: accuracy of 18FDG PET-CT for distant metastasis staging in lung cancer patients: SurgOncol. 2013 Sep; 22(3):151-5.
Michael Lin , Chaitanya Ambati. The management impact of clinically significant incidental lesions detected on staging FDG PETCT in patients with non-small cell lung cancer (NSCLC): an analysis of 649 cases. Lung Cancer 2012;76(3):344–349.
Gould MK, Kuschner WG, et al. Test performance of positron emission tomography and computed tomography for
mediastinal staging in patients with non-small-cell lung cancer: A meta-analysis. Ann Intern Med 2003,139(11):879–
Andrea Billé , Ettore Pelosi, at al. Preoperative intrathoracic lymph node staging in patients with non-small-cell lung cancer: accuracy of integrated positron emission tomography and computed tomography : Eur J Cardiothorac Surg 2009 Sep;36(3):440-5.
Didier Lardinois1, Walter Weder, et al. Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomographyN Engl J Med. 2003 Jun 19;348(25):2500-7.
Sung Shine Shim 1, Kyung Soo Lee, et al. Non-small cell lung cancer: prospective comparison of integrated FDG PET/CT and CT alone for preoperative staging. Radiology. 2005 Sep;236(3):1011-9.
Henry Knipe, Radswiki et al. Fleischner Society pulmonary nodule recommendations: 2017 revision
Wahl RL, Jacene H, et al.:From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors J Nucl Med. 2009 May;50 Suppl 1(Suppl 1):122S-50S
Qiyong Ding, Xu Cheng, et al. PET/CT evaluation of response to chemotherapy in non-small cell lung cancer: PET response criteria in solid tumours (PERCIST) versus response evaluation criteria in solid tumours (RECIST) : J Thorac Dis 2014 Jun;6(6):677-83.
David L. Chana, Stephen J. Clarkea, et al. Prognostic and predictive biomarkers in neuroendocrine tumours. Department of Critical Reviews in Oncology/Hematology 113 (2017) 268–282.
